The indirect immunofluorescence (IIF) and line immunoassay (LIA) methods are used to detect antinuclear antibodies (ANA) and certain other autoantibodies in the screening and diagnosis of systemic autoimmune diseases. Although autoantibodies detected by IIF or LIA are not essential for the diagnosis of RA, they are usually used to help differentiate RA from other autoimmune disorders. Based on previously reported results, 9 approximately 20% to 40% of patients with RA express ANA, as detected via IIF. However, studies on the relationships between RA and autoantibodies have focused on RF and anti-CCP, which are included among the diagnostic criteria for RA. Two reports 10, 11 have compared the profiles for the pattern or autoantibodies identified using IIF and LIA. However, the studies detailed in previous reports differ from our research because those studies target a general population 10 or use LIA, which detects only RA-specific antibodies such as AFAs.
11 Despite the frequent use of IIF or commercial LIAs for screening or diagnosis of many autoimmune diseases, including RA, the relationship between the pattern or intensity of IIF and the autoantibodies identified by LIA in patients with RA has not been evaluated, nor has their relationship to currently used autoantibodies, such as RF and anti-CCP.
The aims of this study were to analyze the IIF pattern of autoantibodies identified by LIA in a group of patients in whom RA has been established; to compare the autoantibody profiles detected by IIF or LIA with the results of commonly used serological tests such as RF, anti-CCP, and inflammatory markers of disease activity; and to provide information on the relationships between autoantibodies detected in RA and their association with disease-activity markers.
Materials and Methods

Patients
Between January and June 2012, 153 serum samples were obtained from patients with known RA who had been referred for blood chemistry or immunologic laboratory testing. Rheumatologists made diagnoses according to clinical presentation and laboratory results (ACR 1987 criteria 12 ). All of the subjects in this study were diagnosed as having seropositive rheumatoid arthritis (SPRA). Specimens submitted for ESR, CRP, RF, and ANA, using IIF and LIA for diagnosis or follow-up monitoring of RA, were used in this study. Twenty-two men and 131 women were included. The mean age was 54.1 (SD, 12.6; range, years and the average duration of disease was 6.4 (SD, 5.9; range, 0.1-31.0) years. The therapeutic regimens for the patients are described in Table 1 .
Laboratory Tests
Measurement of Acute Phase Response and Serological Markers
Measurement of RF and CRP were performed using the Hitachi 7600-110 automated chemistry analyzer (Hitachi High-Technologies Corporation, Tokyo, Japan) using RF-LATEX X1 (Denka Seiken Co. Ltd., Tokyo, Japan) and Pure Auto S CRP latex (Sekisui Medical Co. Ltd., Tokyo, Japan), respectively. Anti-CCP was measured using the Architect i1000SR (Abbott Laboratories, Abbott Park, IL). The ESR was measured using Test-1TH (Alifax S.p.a., Polverara, Italy).
The reference ranges established at the laboratory for ESR and CRP were: ESR, men, ≤15 mm/hour; women, ≤20 mm/hour; CRP, <0.5 mg/dL. RF and anti-CCP were interpreted according to the 2010 ACR/EULAR criteria for RA as negative, which is the upper limit of normal (ULN) or less; low-positive, higher than the ULN but 3-fold the ULN or less; and high-positive, greater than 3-fold the ULN.
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The ULN for the laboratory and assay was 18 IU/mL for RF and 5 U/mL for anti-CCP.
IIF Method
Serum samples were diluted (1:40) with phosphate buffer before application to HEp-2 cell slides (Kallestad; Bio-Rad Laboratories, Hercules, CA). Tests were performed using the PhD System (Bio-Rad Laboratories) according to the instructions provided by the manufacturer. Two experts (S.Y.K. and J.J.Y.) at the Department of Laboratory Medicine interpreted the IIF results using a Nikon fluorescence microscope (Nikon Corporation, Tokyo, Japan). Fluorescence intensity was scored semiquantitatively from negative to 4+, relative to the intensity of positive (4+ and 1+) and negative controls at ×200.
The IIF pattern was classified as speckled, dense fine speckled (DFS), homogeneous, cytoplasmic, nucleolar, discrete speckled (DS), or other pattern according to Science contemporary nomenclature using HEp-2 cells. 10 The DFS pattern was defined as interphase nucleoplasmic staining accompanied by positivity on most of the chromatin plates of metaphase cells. 10, 11 The cytoplasmic pattern included various cytoplasmic staining patterns, such as diffuse or fine speckled, mitochondrial-like, lysosomallike, Golgi-like, and cytoskeletal cytoplasmic patterns. Patterns classified as "other" included nuclear dots, centriole, and mitotic apparatus patterns.
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LIA
We used the EUROIMMUN ANA Profile 3 Euroline kit (EUROIMMUN AG, Lübeck, Germany) to perform the LIA. In brief, the system includes nylon strips coated with recombinant purified antigens in distinct lines with a plastic backing. The antigens include: nuclear ribonucleoprotein (nRNP/ Sm, SS-A, Ro-52, SS-B,topoisomerase I (Scl-70), PM-Scl, proliferating cell nuclear antigen (PCNA), Jo-1, centromere protein B (CENP-B), double-stranded DNA (dsDNA), nucleosomes, histones, ribosomal protein P, and antimitochondrial antibodies (AMA-M2s). The nylon strip was incubated with serum at a 1:101 dilution. After specific autoantibodies in the patient sera were bound to the corresponding antigen sites, the strip was incubated with an enzyme conjugate to produce a color reaction. EUROLineScan software, version 3.33 (EUROIMMUN US, Morris Plains, NJ), was used to evaluate the signal intensity; the results were graded from negative to 3+.
Statistical Analysis
We performed statistical analyses using SPSS software, version 15.0 (SPSS Inc., Chicago, IL); all data were expressed as mean (SD). We used the Student's t-test, analysis of variance (ANOVA), and the Kruskal-Wallis test for continuous variables and used the Pearson χ 2 test and linear-by-linear association for nominal variables to evaluate differences between study groups. We performed correlation analyses between markers for disease activity and the presence of autoantibodies. A 2-sided P value of less than .05 was considered statistically significant. Categorizing patients according to their therapeutic regimen did not reveal differences in positivity via IIF or LIA. Also, grouping patients based on ESR or CRP, or RF levels did not reveal any differences in the rates of positivity via IIF or LIA. Only IIF demonstrated an increased positivity in the anti-CCP-positive group compared with the anti-CCPnegative group (P = .03), positivities of the LIA results in these two groups were similar.
Comparison Between the Results of IIF and LIA
The most frequent IIF pattern in patients with RA was a homogenous pattern, observed in 32 patients (20.9%), followed by 26 patients (17.0%) with a DFS pattern, 11 (7.2%) with speckled patterns, and 9 (5.9%) with cytoplasmic patterns ( Science frequency ( Table 3) . Anti-SS-A and anti-Ro-52 were the most frequently identified antibodies regardless of the IIF pattern, even in patients who had tested negative via IIF ( Table 4 ). The intensities of the positive bands in LIA were 3+ in 43.8% of cases, 2+ in 23.3%, and 1+ in 32.9%. We found no significant correlation in intensity via linear-bylinear association analysis between IIF and LIA (P = .36).
Among the 77 patients who tested negative via IIF, 59
(76.6%) tested negative via LIA, with the remaining 18 patients showing autoantibodies in their sera, as identified via LIA. Anti-SS-A (13.0%) was the most commonly identified autoantibody, followed by anti-Ro-52 (6.5%; 
Comparison Between Serologic and Inflammatory Markers of RA
CRP levels in the study subjects were significantly correlated with ESR (P <.01, r = 0.51), RF (P = .02, r = 0.18), and anti-CCP (P = .02, r = 0.20). ESR correlated with RF (P <.01, r = 0.27) and anti-CCP (P <.01, r = 0.23); RF and anti-CCP were not correlated (P = .14).
When analyzing disease activity markers or serologic markers according to IIF and LIA results, the ESR, RF, and CRP did not differ based on the pattern or increase in fluorescence intensity via IIF. In contrast, anti-CCP showed a tendency to increase depending on IIF intensity (P <.01) and was higher in cases showing homogenous and cytoplasmic IIF patterns. There were no differences in the ESR, RF, CRP, or anti-CCP, when subjects are grouped by autoantibody type or band intensity ( Table 5 and Table 6 ).
Discussion
In this study, the positive rates or intensities of autoantibodies as measured by IIF or LIA were not affected by differences in therapeutic regimen, disease activity reflected by CRP level or ESR, or increases in other autoantibodies such as RF. Not only has anti-CCP shown a correlation to disease activity as reflected by CRP level or ESR but also, only anti-CCP demonstrated a positive correlation with increasing IIF positivity and intensity. This supports the finding that anti-CCP antibodies are important for the progression of bone destruction. 14,15 Although almost half (49.7%) of the patients with RA in our cohort displayed autoantibodies that are detectable via IIF, commercial LIA kits detected specific autoantibodies in only 34.0% of cases. The most frequent IIF patterns were the homogenous and DFS; 65.6% of homogenous and 80.8% of DFS pattern cases did not include identified autoantibodies, as detected by the commercial LIA used in this study.
Antibodies that cause homogenous patterns by IIF are those against dsDNA, ssDNA, histone, Scl-70, and other entities. 9, 16, 17 The DFS pattern is caused by anti-DFS70, corresponding to the 70 kDa DNA-binding transcription coactivator p75, which is also known as lens epitheliumderived growth factor (LEDGF).
13,18-20 In our study, most patients with a homogenous pattern via IIF did not have a specific autoantibody identified by LIA; we observed only 2 cases of anti-dsDNA antibodies and 1 case of antihistone antibodies. Methods other than LIA were not used in this study to confirm the identification of autoantibodies and the reported sensitivity levels of LIA for anti-dsDNA and antihistone autoantibodies are somewhat lower (55.4% 21 and 78%, 22 respectively) than for other autoantibodies included in the commercial LIA kit.
22 However, the homogenous pattern in RA, as detected via IIF, indicates the presence of other, unknown antibodies in addition to anti-dsDNA and antihistone antibodies. Also, the DFS70 antigen is not included in the commercial LIA kit; this indicates that not all of the DFS patterns resulted from anti-DFS70. However, the reported frequency of anti-DFS70 in RA is 0%; 17,23 this implies the presence of another autoantibody associated with the DFS pattern in patients with RA.
Anti-SS-A (22.2%) was the most frequently identified autoantibody via LIA in our study, followed by anti-Ro-52 (11.1%). Irrespective of the IIF pattern, anti-SS-A and/or anti-Ro-52 were the most frequently detected autoantibodies in patients with RA. Anti-SS-A is found in 40-94% of patients with Sjögren syndrome, and in 20-60% of patients with systemic lupus erythematosus (SLE).
24 According to unpublished data from our laboratory, anti-SS-A is the most commonly identified autoantibody in many systemic autoimmune diseases; it is present in 79% of Science patients with Sjögren syndrome, 47% with SLE, and 43% with overlap syndrome. The frequency of anti-SS-A in RA (22.2%) is low compared with other systemic autoimmune diseases, although it is slightly higher than the frequency (15.5%) reported in the general population.
25 Anti-Ro-52 is the second most commonly observed autoantibody in systemic autoimmune diseases; it has been reported in 67% of Sjögren-syndrome cases, 42% of SLE cases, and 43% of overlap-syndrome cases. As with anti-SS-A, the frequency of anti-Ro-52 in RA (11.1%) is much lower than in the systemic autoimmune diseases and is somewhat higher than in patients without autoimmune diseases (5.8%; data not shown).
Anti-Ro-52 is detected with higher frequency in Sjögren syndrome, systemic sclerosis (SSc), and myositis 26 and is associated with nonautoimmune diseases such as viral infections and neoplastic diseases.
27 Ro-52 has the ability to provoke an immune response and is recognized as the most antigenic protein known in humans.
28 Despite these observations, RA has low frequencies of anti-SS-A and anti-Ro-52 positivity; this is considered a serological characteristic of RA.
In our study, half the types of autoantibodies detected via IIF in patients with RA could not be identified via the commercial LIA method we used. Unlike other autoimmune disorders that can be identified by a specific autoantibody or a major disease-specific pattern via IIF, the autoantibodies found in patients with RA were nonspecific and did not demonstrate a predominant IIF pattern; these observations did not differ by disease activity or therapeutic regimen. Because a specific or dominant positive IIF pattern or autoantibody was not found in RA, neither IIF nor LIA were diagnostic for RA. However, these tests are still needed to screen for the presence of autoimmune disease and to differentiate RA from other systemic autoimmune diseases. Overall, however, our results indicate that IIF and LIA are inadequate for the diagnosis of RA and the monitoring of its disease activity.
This study has certain limitations. Despite the lack of reference methods or reference materials, not performing cross-validation against another method to confirm the presence of autoantibodies identified by LIA is a limitation. Also, the identification of autoantibodies via LIA was limited to 15 autoantibodies, including anti-extractable Science nuclear antigens. Additionally, longitudinal follow-up data according to disease progression were not available due to the cross-sectional nature of this study. Thus, the predictive and prognostic value of the autoantibodies identified via IIF or LIA could not be determined.
In summary, a specific or dominant IIF pattern was not identified by LIA in patients with RA; this was in contrast to the results observed with other major systemic autoimmune diseases. Patients with RA had lower frequencies of anti-SS-A and anti-Ro-52 than that which one would expect to see in other systemic autoimmune diseases; these lower frequencies are considered to be serologically characteristic of RA. Also, positive rates or intensities of autoantibodies detected via IIF or LIA did not differ by therapeutic regimen or disease activity in our study subjects, as reflected by CRP level or ESR. IIF and LIA results appear to be insufficient for the diagnosis of RA and monitoring of disease activity, although these methods are still useful as part of screening for the presence of autoimmune diseases and to differentiate RA from other systemic autoimmune diseases. LM
